Tecentriq was combined with Avastin and chemotherapy as initial treatment
First new drug approach to depression in two decades, company says
Six million affected today, 15 millions four decades from now
Once-weekly GLP-1 receptor agonist to be available in early 2018
Setback follows announcement of adverse patient outcomes with dengue vaccine
New technology would allow oral dosing of drugs typically administered by injection
Agency aims to reduce the cost of expensive drugs and treatments
New study confirms a dramatic decrease in infant deaths
RT002 met primary and all secondary endpoints in pivotal trials for glabellar lines
Merger partners say they’ll be able to push down drug costs


Right or Left? In Colorectal Cancer, Side Matters

Eric Van Cutsem, MD, PhD, Co-Chairman of the 2017 ESMO World Congress on Gastrointestinal Cancer, explains why side matters in colorectal cancer. Left-sided tumors have different and often better outcomes, responding better to some therapies than their right-side counterparts. However, research is zeroing in on treatments to fight right-side tumors more effectively.

2017 ESMO World Congress on Gastrointestinal Cancer

P&T December 2017
Table of Contents


But Drug Companies and Some Patient Groups Want Changes
State “Right to Try” laws, which allow terminally ill patients to seek investigational treatments under certain circumstances, have created pressure for Congress to follow up with a federal law. Though facing opposition from patient advocates and the drug industry, a bill passed by the Senate is now making its way to the House.
Nanopharmaceuticals, many of which are already in clinical use, can impart pharmacokinetic, efficacy, safety, and targeting benefits compared with conventional drug formulations. We present FDA-approved and investigational nanodrugs, their structures and benefits, and the many challenges they face in development.
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a severe reduction in peripheral blood platelet count. This article reviews the pathophysiology of ITP and summarizes the updates in ITP management and treatment.
Pipeline Plus
Despite the many medications already available, patients with heart failure often have disease exacerbations, reduced quality of life, and increased mortality, highlighting the need for new treatment approaches. We explore drugs currently in development.
Hospital-acquired and ventilator-associated pneumonia continue to represent the most common nosocomial-associated infections. The authors consider the recent IDSA guidelines for diagnosis and management, and outline the key points of change.
Season’s Greetings


Prescription: Washington
Over-the-counter products in line for user fee program
Medication Errors
Epinephrine for anaphylaxis: Autoinjector or 1-mg vial or ampoule?
New Drugs/Drug News
Approvals, new indications, regulatory activities, and more
Secnidazole (Solosec) for the one-dose treatment of bacterial vaginosis; triamcinolone acetonide extended-release injection (Zilretta) for osteoarthritis knee pain; and insulin aspart injection (Fiasp), a rapidacting human insulin analogue for glycemic control in diabetes mellitus
Drug Forecast
Bezlotoxumab (Zinplava) to prevent the recurrence of Clostridium difficile infection